Literature DB >> 16460139

How much is the cost of visual impairment: caveat emptor.

Catherine Meads1, Chris Hyde.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16460139     DOI： 10.2165/00019053-200624020-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  10 in total

Review 1.  NICE: faster access to modern treatments? Analysis of guidance on health technologies.

Authors:  J Raftery
Journal:  BMJ       Date:  2001-12-01

Review 2.  Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation.

Authors:  C Meads; C Salas; T Roberts; D Moore; A Fry-Smith; C Hyde
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

3.  Unhealthy spin.

Authors:  Bob Burton; Andy Rowell
Journal:  BMJ       Date:  2003-05-31

4.  How to make a compelling submission to NICE: tips for sponsoring organisations.

Authors:  Amanda Burls; Josie Sandercock
Journal:  BMJ       Date:  2003-12-20

Review 5.  What is the cost of blindness?

Authors:  C Meads; C Hyde
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

6.  Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.

Authors:  A H Miners; Martina Garau; Dogan Fidan; A J Fischer
Journal:  BMJ       Date:  2004-12-15

7.  Direct costs of blindness in Australia.

Authors:  S E Wright; J E Keeffe; L S Thies
Journal:  Clin Exp Ophthalmol       Date:  2000-06       Impact factor: 4.207

8.  The burden of age-related macular degeneration: results of a cohort study in two French referral centres.

Authors:  Julia Bonastre; Claude Le Pen; Gisèle Soubrane; Gabriel Quentel
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.

Authors:  Antoine Lafuma; Antoine Brézin; Stefania Lopatriello; Klaus Hieke; Julia Hutchinson; Viviane Mimaud; Gilles Berdeaux
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 10.  Coronary artery stents: a rapid systematic review and economic evaluation.

Authors:  R Hill; A Bagust; A Bakhai; R Dickson; Y Dündar; A Haycox; R Mujica Mota; A Reaney; D Roberts; P Williamson; T Walley
Journal:  Health Technol Assess       Date:  2004-09       Impact factor: 4.014
  10 in total
  1 in total

Review 1.  The economic implications of glaucoma: a literature review.

Authors:  Jordana K Schmier; Michael T Halpern; Mechelle L Jones
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.